Literature DB >> 832540

Surgical suppurating infections and surgical abdominal infections treated with fosfomycin.

A Gallardo, J M Sáez, G Enriquez, A R Cobacho, R Torronteras, C Recordan, A Del Moral, A Arroyo, A G Curiel.   

Abstract

Two groups of patients suffering surgical infections were treated with fosfomycin. The first includes 21 suppurating dermic of soft underlying tissue lesions. The second group includes 29 surgical abdominal infections. The bacteriology of the first group was made up of gram-positive and gram-negative germs predominantly S. aureus and E. coli, all the isolated species appeared to be sensitive to fosfomycin. In the second group a gram-negative bacterial flora predominantly E. coli was obtained; with a sensitivity to this antibiotic of 90.5%. Surgical treatment accompanied the treatment with fosfomycin. In the first group, all the patients were cured with the oral administration of 2-6 g/day and in an average time less than that of the similar control group which did not receive the antibiotic. In the second group surgical treatment was necessary in 25 of the 29 patients and in all of them parenteral treatment was done with fosfomycin, preferably intramuscularly and in general the dosage was 4 g daily. All patients were cured except for one who was not operated on and who suffered from a fever of undetermined origin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832540     DOI: 10.1159/000222080

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

1.  Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

Authors:  M Frossard; C Joukhadar; B M Erovic; P Dittrich; P E Mrass; M Van Houte; H Burgmann; A Georgopoulos; M Müller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.

Authors:  Dmitri Iarikov; Ronald Wassel; John Farley; Sumathi Nambiar
Journal:  Infect Dis Ther       Date:  2015-10-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.